Prion diseases are fatal neurodegenerative diseases that occur either spontaneously or genetically or are caused by infection. Spontaneously occuring prion diseases are age related. The infectious agents, called prions, are proteinaceous infectious particles, composed mainly of the host-encoded prion protein (PrP) in a misfolded, insoluble, and aggregated isoform. Advanced glycation end products (AGEs) are well known to contribute to protein misfolding, insolubility, and aggregation. Thus, we studied if AGE-modification could influence PrP aggregation. We analyzed PrP preparations immunochemically to determine if they contain AGE-modified PrP. We also studied the influence of AGE modifications on the PrP aggregation process in vitro.
Get full access to this article
View all access options for this article.
References
1.
PrusinerSB. Prions. Proc Natl Acad Sci USA, 1998; 95:13363–13383.
DumpitakC, BeekesM, WeinmannN, MetzgerS, WinklhoferKF, TatzeltJ, RiesnerD. The polysaccharide scaffold of PrP 27–30 is a common compound of natural prions and consists of alpha-linked polyglucose. Biol Chem, 2005; 386:1149–1155.
KikuchiS, ShinpoK, TakeuchiM, YamagishiS, MakitaZ, SasakiN, TashiroK. Glycation—a sweet tempter for neuronal death. Brain Res Brain Res Rev, 2003; 41:306–323.
6.
MunchG, Deuther-ConradW, Gasic-MilenkovicJ. Glycoxidative stress creates a vicious cycle of neurodegeneration in Alzheimer's disease—a target for neuroprotective treatment strategies?J Neural Transm Suppl, 2002; 62:303–307.
7.
CastellaniR, SmithMA, RicheyPL, PerryG. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res, 1996; 737:195–200.
8.
GafnA. Structural modifications of proteins during aging. J Am Geriatr Soc, 1997; 45:871–880.
9.
HarringtonCR, ColacoCA. Alzheimer's disease. A glycation connection. Nature, 1994; 370:247–248.
10.
BoumaB, Kroon-BatenburgLM, WuYP, BrunjesB, PosthumaG, KranenburgO, de GrootPG, VoestEE, GebbinkMF. Glycation induces formation of amyloid cross-beta structure in albumin. J Biol Chem, 2003; 278:41810–41819.
11.
PrusinerSB, McKinleyMP, BowmanKA, BoltonDC, BendheimPE, GrothDF, GlennerGG. Scrapie prions aggregate to form amyloid-like birefringent rods. Cell, 1983; 35:349–358.
12.
PanKM, StahlN, PrusinerSB. Purification and properties of the cellular prion protein from Syrian hamster brain. Protein Sci, 1992; 1:1343–1352.
13.
ElfrinkK, Nagel-StegerL, RiesnerD. Interaction of the cellular prion protein with raft-like lipid membranes. Biol Chem, 2007; 388:79–89.
14.
StohrJ, WeinmannN, WilleH, KaimannT, Nagel-StegerL, BirkmannE, PanzaG, PrusinerSB, EigenM, RiesnerD. Mechanisms of prion protein assembly into amyloid. Proc Natl Acad Sci USA, 2008; 105:2409–2414.
15.
ThornalleyPJ, Yurek-GeorgeA, ArgirovOK. Kinetics and mechanism of the reaction of aminoguanidine with the α-oxoadehydes glyoxal, methylglyoxal and 3-deoxyglucosone under physiological conditions. Biochem Pharmacol, 2000; 60:55–65.
16.
WinklhoferKF, TatzeltJ. Cationic lipopolyamines induce degradation of PrPSc in scrapie-infected mouse neuroblastoma cells. Biol Chem, 2000; 381:463–469.
MellinghoffAC, ReiningerAJ, WuerthJP, FoundsHW, LandgrafR, HeppKD. Formation of plasma advanced glycosylation end products (AGEs) has no influence on plasma viscosity. Diabet Med, 1997; 14:832–836.
19.
PanzaG, StohrJ, DumpitakC, PapathanassiouD, WeissJ, RiesnerD, WillboldD, BirkmannE. Spontaneous and BSE-prion-seeded amyloid formation of full length recombinant bovine prion protein. Biochem Biophys Res Commun, 2008; 373:493–497.
20.
BirkmannE, SchaferO, WeinmannN, DumpitakC, BeekesM, JackmanR, ThorneL, RiesnerD. Detection of prion particles in samples of BSE and scrapie by fluorescence correlation spectroscopy without proteinase K digestion. Biol Chem, 2006; 387:95–102.
21.
SuyamaK, YoshiokaM, AkagawaM, MurayamaY, HoriiH, TakataM, YokoyamaT, MohriS. Prion inactivation by the Maillard reaction. Biochem Biophys Res Commun, 2007; 356:245–248.
